What a month-long sleep trial found
Difficulty falling asleep and staying asleep can affect concentration, mood and everyday functioning. Researchers continue to investigate treatments that target the biological systems controlling wakefulness.
A newly published phase 2 clinical trial tested the insomnia medicine lemborexant in Korean adults whose sleep was assessed overnight in a laboratory.
The study involved 64 participants in its full analysis set and compared two doses of the medicine with a placebo over 30 days.
Researchers reported improvements in several objective sleep measurements with lemborexant compared with placebo, including the time taken to reach sustained sleep.
The findings appeared in Scientific Reports on 17 October 2026 and provide evidence from a relatively small, short-duration trial.
They do not establish that the medicine is suitable for everyone with insomnia, or that its long-term effects can be inferred from a one-month study.
Insomnia involves more than a late bedtime
Insomnia disorder is characterised by persistent difficulty initiating sleep, maintaining sleep or obtaining restorative sleep despite having an opportunity to rest.
People may spend long periods awake after going to bed or wake repeatedly during the night.
The consequences can extend into the day, including fatigue, reduced attention and frustration about sleep.
Because insomnia can have different contributing factors, treatment decisions require attention to the person’s wider health and circumstances.
Sleep research often distinguishes between what participants report and what laboratory measurements reveal.
The Korean trial used polysomnography, a method that records physiological signals during sleep, to measure several outcomes directly.
This approach provides a structured way to assess whether a treatment changes sleep patterns beyond participants’ impressions alone.
The medicine targets wakefulness signalling
Lemborexant belongs to a class of medicines known as dual orexin receptor antagonists.
Orexin is involved in promoting wakefulness, and blocking its receptors can reduce signalling that helps maintain an alert state.
This is different from simply measuring whether someone feels sleepy after taking a medicine.
The trial investigated whether the treatment changed objectively measured sleep initiation and maintenance.
The researchers studied doses of five milligrams and ten milligrams, referred to as LEM5 and LEM10.
These are the doses used in the research, not personalised prescribing recommendations.
People considering treatment for insomnia should discuss options, possible adverse effects and contraindications with an appropriately qualified clinician.
The study should not be used as a reason to start, stop or adjust prescription medication independently.
How the trial was organised
The study was a multicentre, randomised, double-blind, placebo-controlled, parallel-group clinical trial.
Randomisation assigned participants to treatment groups rather than allowing them to choose which medicine they received.
Double blinding was intended to reduce the influence of expectations on participants and investigators.
A placebo group helped researchers distinguish treatment-related changes from improvements that might occur for other reasons.
Participants were Korean adults aged between 19 and 80 years who met the study’s criteria for insomnia disorder.
The investigators required sleep efficiency of no more than 85 percent and a latency to persistent sleep of at least 30 minutes.
These entry criteria selected people with measurable sleep difficulties and therefore limit generalisation to everyone who occasionally sleeps poorly.
The trial is registered as NCT05594589.
Three groups and a month of treatment
Participants were randomly allocated in a ratio of two to two to one across the five-milligram, ten-milligram and placebo groups.
The full analysis set included 25 people receiving five milligrams, 26 receiving ten milligrams and 13 receiving placebo.
Those numbers total 64 participants.
The medicine or placebo was taken immediately before bedtime over 30 days.
Before treatment assessment, participants completed an approximately 14-day single-blind placebo run-in period.
Researchers used overnight polysomnography to establish baseline measurements and then assessed outcomes again at day 30.
The study’s design allowed the two active-dose groups to be compared against a smaller placebo group.
Because the groups were small, uncertainty around individual outcome estimates remains important.
What the researchers measured
The primary endpoint concerned latency to persistent sleep for the five-milligram dose.
Latency to persistent sleep measures the time from the start of the recording period until a sustained period of sleep is reached.
A shorter latency generally indicates that a participant was able to settle into sustained sleep more quickly.
The same measurement was a secondary endpoint for the ten-milligram group.
Researchers also evaluated sleep efficiency, which is the percentage of time in bed spent asleep.
Another exploratory outcome was wake after sleep onset, or WASO, which measures minutes spent awake after initially falling asleep.
Total sleep time was also assessed as an exploratory outcome.
These measures capture different aspects of sleep and should not be treated as interchangeable.
Falling asleep appeared easier with treatment
At day 30, reductions in latency to persistent sleep were larger in the lemborexant groups than in the placebo group.
This finding indicates that the active-treatment groups showed greater improvement in reaching sustained sleep under the trial conditions.
The study abstract does not provide a single headline figure showing the absolute number of minutes saved across all participants.
It would therefore be misleading to claim that every patient fell asleep a specific number of minutes faster.
The direction of the reported effect is clear, but the size of the benefit for an individual depends on the detailed estimates and clinical context.
The primary endpoint was defined for the five-milligram group, while the corresponding ten-milligram analysis had a different endpoint designation.
That distinction matters when interpreting the strength of the evidence for each dose.
The study supports further consideration of the treatment rather than a blanket guarantee of rapid sleep onset.
Staying asleep was another important outcome
Researchers also examined wake after sleep onset, which reflects how much time someone spends awake after first falling asleep.
The trial reported larger reductions in this measure with lemborexant than with placebo.
This suggests a potential benefit for sleep maintenance, not only for the process of initially falling asleep.
Sleep maintenance problems can be particularly frustrating because a person may fall asleep normally and still experience an interrupted night.
However, the outcome was classified as exploratory in the study.
Exploratory measurements can provide useful evidence, but they should be interpreted with appropriate caution.
A short trial also cannot determine whether improvements remain unchanged over many months or years.
Longer follow-up is needed to evaluate the durability of treatment effects.
Sleep efficiency and total sleep time
The researchers reported larger increases in sleep efficiency in the active-treatment groups compared with placebo.
Sleep efficiency expresses time spent asleep as a proportion of the time allocated for sleep.
For example, a person who sleeps for seven hours during eight hours in bed has a sleep efficiency of 87.5 percent.
That numerical example explains the measure; it is not a result from the trial.
Total sleep time also increased more with lemborexant than with placebo in the reported analysis.
Together, these outcomes suggest improvements across several dimensions of objectively measured sleep.
They do not imply that all participants reached a particular number of hours or that everyone responded similarly.
Averages can conceal differences between individual patients, including people who benefit little or experience unwanted effects.
Why the placebo comparison matters
Sleep can change from one night to another because of stress, routines, environment and many other factors.
Participants entering a trial may also improve simply because they receive more attention or adopt more consistent sleep schedules.
Comparing an active medicine with a placebo helps account for some of these influences.
The randomised design strengthens the study’s ability to evaluate whether the observed differences are attributable to the treatment.
However, the strength of a randomised comparison also depends on sample size, measurement quality and follow-up.
With 13 people in the placebo group, the reference sample was relatively small.
The results therefore add to clinical evidence without removing uncertainty about uncommon outcomes or patient subgroups.
A larger trial could provide more precise estimates and better assess whether different characteristics influence response.
What the safety findings can and cannot tell us
The authors reported that lemborexant was well tolerated during the trial.
That is encouraging within the limited population and one-month observation period.
However, 64 participants are not enough to reliably detect uncommon adverse effects.
The trial also does not establish the safety of long-term use, use in every age group or use alongside all other medicines.
Medicines affecting wakefulness may require particular care in people with medical conditions or occupations where alertness is critical.
The study abstract does not provide a detailed breakdown of every adverse event, so it would be inappropriate to invent one.
Safety assessments need to consider the full prescribing information and the patient’s circumstances.
A clinician can help determine whether a medicine’s expected benefits outweigh its potential risks.
How this differs from everyday sleep advice
Insomnia management is not limited to medication.
Assessment may consider sleep schedules, environmental factors, mental health, other medical conditions and treatments already being used.
Behavioural approaches, including cognitive behavioural therapy for insomnia, are important components of evidence-based care.
The Korean study did not compare lemborexant directly against every behavioural treatment or every other sleep medicine.
It therefore cannot establish that the tested medicine is the best option for all patients.
Its contribution is more specific: a controlled comparison of two doses against placebo using objective sleep measurements.
Readers should distinguish the outcome of that comparison from broader decisions about managing chronic insomnia.
Individual care should be guided by qualified healthcare professionals.
Why the Korean population matters
The study specifically enrolled Korean adults with insomnia disorder.
Conducting research in different populations can help clinicians assess whether findings observed elsewhere are applicable to their patients.
Nevertheless, one national sample cannot represent the full diversity of people with insomnia worldwide.
Age, other health conditions, concurrent medicines and lifestyle factors may influence treatment decisions.
The participants were also selected according to measurable sleep criteria.
Someone with occasional difficulty sleeping may not resemble the participants included in the trial.
The findings are therefore most directly relevant to people meeting similar diagnostic and study criteria.
Further research across broader populations would help establish how consistently the reported benefits appear.
Important limitations of the evidence
The full analysis set contained 64 participants, with only 13 assigned to placebo.
Treatment lasted 30 days, making the trial informative about short-term outcomes rather than long-term effectiveness.
Participants were adults in South Korea who met specified polysomnographic thresholds.
The study did not test children or people without insomnia disorder.
Several outcomes were secondary or exploratory rather than the designated primary endpoint.
The available abstract reports the direction of the results but not every numerical estimate or confidence interval.
The findings should therefore not be simplified into an unsupported percentage improvement or a promised number of extra hours of sleep.
Larger studies and careful clinical interpretation remain necessary.
What the findings add to insomnia research
The trial contributes controlled evidence about a medicine that acts on the brain’s wakefulness signalling system.
Researchers measured sleep using laboratory recordings rather than relying only on self-reported improvement.
Across the reported outcomes, both active-dose groups showed greater changes in sleep onset and maintenance measures than placebo.
The authors concluded that the findings support the clinical applicability of lemborexant as a treatment option for insomnia management in South Korea.
That conclusion should be read alongside the trial’s size, duration and eligibility criteria.
The research does not replace medical assessment or establish a universal treatment recommendation.
Its clearest contribution is evidence that the tested intervention improved several objective sleep measures during a month-long controlled trial.
Future studies can clarify longer-term outcomes, safety and which patients are most likely to benefit.
Source Information
Study: A phase 2 trial evaluating polysomnography outcomes and safety of lemborexant in Korean adults with insomnia disorder.
Authors: Yong Won Cho, In-Young Yoon, YoungJi Pyo, Takao Takase, Naoki Kubota, Margaret Moline and colleagues.
Journal: Scientific Reports.
Publication date: 17 October 2026.
Methods: One-month multicentre, randomised, double-blind, placebo-controlled phase 2 study in 64 Korean adults with insomnia disorder. ClinicalTrials.gov registration NCT05594589.
